Don Foster

997 total citations · 1 hit paper
16 papers, 476 citations indexed

About

Don Foster is a scholar working on Cardiology and Cardiovascular Medicine, Molecular Biology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Don Foster has authored 16 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cardiology and Cardiovascular Medicine, 7 papers in Molecular Biology and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Don Foster's work include Renin-Angiotensin System Studies (8 papers), Hormonal Regulation and Hypertension (6 papers) and RNA modifications and cancer (4 papers). Don Foster is often cited by papers focused on Renin-Angiotensin System Studies (8 papers), Hormonal Regulation and Hypertension (6 papers) and RNA modifications and cancer (4 papers). Don Foster collaborates with scholars based in United States, Netherlands and Australia. Don Foster's co-authors include Stephen A. Huang, Akshay S. Desai, Jörg Täubel, George L. Bakris, David J. Webb, Gabriel J. Robbie, Sarah Casey, Marianne T. Sweetser, Sean H. Rhyee and A.H. Jan Danser and has published in prestigious journals such as New England Journal of Medicine, Circulation and Blood.

In The Last Decade

Don Foster

15 papers receiving 470 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension

2023 149 citations Akshay S. Desai, David J. Webb et al. New England Journal of Medicine profile →

Peers

Don Foster

CCM

EDM

SURGE

Kai Hu Germany

Kimberly Hewitt Australia

S. Takami Japan

G Capretti Italy

Ku-Geng Huo Canada

Y Ishimura Japan

Maurice E. Fabiani Australia

Holger Leitolf Germany

Hewang Lee United States

Yoshiko Tahira Japan

Kai Hu Germany

Don Foster

253 ×1.0

238 ×1.2

CCM

180 ×1.6

EDM

43 ×0.6

57 ×1.5

SURGE

Citations per year, relative to Don Foster Don Foster (= 1×) peers Kai Hu

Countries citing papers authored by Don Foster

Since Specialization

Citations

This map shows the geographic impact of Don Foster's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Don Foster with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Don Foster more than expected).

Fields of papers citing papers by Don Foster

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Don Foster. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Don Foster. The network helps show where Don Foster may publish in the future.

Co-authorship network of co-authors of Don Foster

This figure shows the co-authorship network connecting the top 25 collaborators of Don Foster. A scholar is included among the top collaborators of Don Foster based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Don Foster. Don Foster is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Foster, Don, et al.. (2025). Kidney Arteriolar Responses to Liver‐Targeted Small Interference RNA Targeting Angiotensinogen in Diabetic Rats: Comparison With Other Renin‐Angiotensin System Blockers. Journal of the American Heart Association. 14(2). e038326–e038326. 2 indexed citations

Foster, Don, et al.. (2024). Abstract P104: Kidney arteriolar responses to liver-targeted small interference RNA (siRNA) targeting angiotensinogen in diabetic rats: comparison with other renin-angiotensin system blockers. Hypertension. 81(Suppl_1). AP104–AP104.

Desai, Akshay S., David J. Webb, Jörg Täubel, et al.. (2023). Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. New England Journal of Medicine. 389(3). 228–238. 149 indexed citations breakdown →

Uijl, Estrellita, Dien Ye, Liwei Ren, et al.. (2022). Conventional Vasopressor and Vasopressor‐Sparing Strategies to Counteract the Blood Pressure–Lowering Effect of Small Interfering RNA Targeting Angiotensinogen. Journal of the American Heart Association. 11(15). e026426–e026426. 25 indexed citations

Ren, Liwei, Estrellita Uijl, Marian C. Clahsen‐van Groningen, et al.. (2022). Blood pressure‐independent renoprotective effects of small interference RNA targeting liver angiotensinogen in experimental diabetes. British Journal of Pharmacology. 180(1). 80–93. 11 indexed citations

Bovée, Dominique M., Liwei Ren, Estrellita Uijl, et al.. (2021). Renoprotective Effects of Small Interfering RNA Targeting Liver Angiotensinogen in Experimental Chronic Kidney Disease. Hypertension. 77(5). 1600–1612. 22 indexed citations

Uijl, Estrellita, Liwei Ren, Katrina M. Mirabito Colafella, et al.. (2021). No evidence for brain renin–angiotensin system activation during DOCA-salt hypertension. Clinical Science. 135(2). 259–274. 22 indexed citations

Huang, Stephen A., Jörg Täubel, Giuseppe Fiore, et al.. (2021). SAFETY, PHARMACODYNAMICS, AND BLOOD PRESSURE EFFECTS OF ALN-AGT, AN RNA INTERFERENCE THERAPEUTIC TARGETING ANGIOTENSINOGEN, IN A RANDOMIZED SINGLE ASCENDING DOSE STUDY OF HYPERTENSIVE ADULTS. Journal of Hypertension. 39(Supplement 1). e8–e8. 5 indexed citations

Uijl, Estrellita, Katrina M. Mirabito Colafella, Liwei Ren, et al.. (2021). CONTROL OF ANTIHYPERTENSIVE EFFECT MEDIATED BY SMALL INTERFERING RNA TARGETING ANGIOTENSINOGEN. Journal of Hypertension. 39(Supplement 1). e15–e15. 1 indexed citations

10.

Huang, Stephen A., Jörg Täubel, Giuseppe Fiore, et al.. (2020). Abstract 14387: Dose-Related Reductions in Blood Pressure With a RNA Interference (RNAi) Therapeutic Targeting Angiotensinogen in Hypertensive Patients: Interim Results From a First-In-Human Phase 1 Study of ALN-AGT01. Circulation. 142(Suppl_3). 14 indexed citations

11.

Uijl, Estrellita, Katrina M. Mirabito Colafella, Yuan Sun, et al.. (2019). Strong and Sustained Antihypertensive Effect of Small Interfering RNA Targeting Liver Angiotensinogen. Hypertension. 73(6). 1249–1257. 88 indexed citations

12.

Uijl, Estrellita, Katrina M. Mirabito Colafella, Ewout J. Hoorn, et al.. (2019). Abstract P2031: Control Of Antihypertensive Effect Of Small Interfering RNA Targeting Angiotensinogen. Hypertension. 74(Suppl_1). 1 indexed citations

13.

Uijl, Estrellita, Katrina M. Mirabito Colafella, Ewout J. Hoorn, et al.. (2018). A3941 Long-lasting small interfering RNA targeting angiotensinogen induces a robust and durable antihypertensive effect. Journal of Hypertension. 36. e17–e17. 1 indexed citations

14.

Chan, Amy, Abigail Liebow, Makiko Yasuda, et al.. (2015). Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification. Molecular Therapy — Nucleic Acids. 4. e263–e263. 108 indexed citations

15.

Haase, Nadine, Don Foster, Stuart Milstein, et al.. (2014). Abstract 666: RNAi Therapeutics Targeting Human Angiotensinogen (hAGT) Ameliorate Preeclamptic Sequelae in an Established Transgenic Rodent Model for Preeclampsia. Hypertension. 64(suppl_1). 3 indexed citations

16.

Akinc, Akin, Alfica Sehgal, Don Foster, et al.. (2011). Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia. Blood. 118(21). 688–688. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact